Study Results Presented at International Transfusion Congress Highlight Cerus Corporation’ Progress Toward Improving the Safety of Platelets, Plasma and Red Blood Cells

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced results of 22 abstracts presenting experiences with the INTERCEPT Blood System for platelets, plasma and red blood cells during the XXXIst International Congress of the International Society for Blood Transfusion in Berlin, Germany held from June 26 to July 1. Studies included data collected in Spain, France, Germany, Italy, Belgium, Sweden, Luxembourg and Scotland, covering a broad range of topics from in vitro results of routine validations to therapeutic efficacy of treated platelets.